Central serous chorioretinopathy treated with topical dorzolamide: A case series study
نویسندگان
چکیده مقاله:
Abstract The aim of this study was to investigate the improvements of central serous chorioretinopathy (CSC) treated with topical dorzolamide. These observational case studies included nine eyes of the nine patients with CSC, treated by a physician with topical dorzolamide consecutively over a one-month period. The central macular thickness and best-corrected visual acuity (BCVA) were measured and compared with baseline values. All the eyes of nine patients demonstrated subretinal fluid (SRF) before or during the treatment course. The SRF was measured and compared with baseline values in this subgroup. Among the cases (n=9), the mean age was reported as 39±6, and BCVA improved in 77% (7 cases), 11.1% (1 case), and 11.1% (1 case) of the cases within two, four, and ten weeks of treatment after the follow-ups, respectively. Indeed, the mean value of central macular thickness showed improvement from 4.72±1.40 to 3.93±9.8 microns (P=0.211). The SRF decreased during follow-up treatment with the mean time of 0.7±0.6 months; however, central macular thickness, choroidal thickness, and BCVA revealed no significant change. Topical dorzolamide might improve BCVA and decrease SRF in patients with CSC. This case series study demonstrated that topical dorzolamide might be effective in the treatment of CSC.
منابع مشابه
Topical Bromfenac in the Treatment of Central Serous Chorioretinopathy
Introduction: CSC is a disorder that is mostly idiopathic, characterized by a serous detachment of the neurosensory retina at the macula, which is caused by active retinal pigment epithelial leakage. Although the exact pathophysiology of CSC has not been clearly elucidated, the primary abnormality leading to RPE disruption and leakage is thought to cause increase choroidal permeability. Studies...
متن کاملA Case of Idiopathic Central Serous Chorioretinopathy in a 12-year-old Male Treated with Bevacizumab
A 12-year-old male presented with a chief complaint of a 1-month-history of decreased visual acuity in his right eye. The patient had no past history of steroid use or other systemic diseases. On fundus examination, which included fluorescent angiography (FAG) and optical coherence tomography (OCT), the patient was diagnosed with idiopathic central chorioretinopathy, whose clinical course was m...
متن کاملTopical Nepafenac in Treatment of Acute Central Serous Chorioretinopathy
This study had been performed to investigate the anatomic and functional outcomes of nepafenac 0.1% therapy in acute central serous chorioretinopathy (CSC). The medical records of 30 patients with acute CSC were reviewed for a total of 31 eye charts. Seventeen eye records of 16 patients who were treated with topical nepafenac 0.1% three times daily for four weeks and continued until complete re...
متن کاملAtypical Central Serous Chorioretinopathy
Bullous central serous chorioretinopathy (CSCR) is a rare variant of CSCR characterized by severe serous retinal detachment which especially involves the inferior quadrants. Corticosteroid therapy administered for systemic or ocular misdiagnoses may induce and exacerbate CSCR. The purpose of this study was to report diagnosis and treatment results of an unusual case of bullous CSCR induced by s...
متن کاملCentral serous chorioretinopathy.
BACKGROUND Central serous chorioretinopathy is a condition typically affecting young adults between 25 and 50 years of age. It is predominating in type A personality trait men. Central serous chorioretinopathy is defined clinically as a detachment of the sensory retina that is commonly unilateral but can also be bilateral. Laser photocoagulation has been used widely with central serous choriore...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ذخیره در منابع من قبلا به منابع من ذحیره شده{@ msg_add @}
عنوان ژورنال
دوره 6 شماره 4
صفحات 0- 0
تاریخ انتشار 2018-12
با دنبال کردن یک ژورنال هنگامی که شماره جدید این ژورنال منتشر می شود به شما از طریق ایمیل اطلاع داده می شود.
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023